Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099538 · ClinicalTrials.gov registry record · Phase 2
Ixekizumab in the Treatment of Bullous Pemphigoid
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03099538: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03099538 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03099538, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.
Interventions
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2019-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099538
The ClinicalTrials.gov registry entry for NCT03099538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixekizumab is the first listed.
NCT03099538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03099538 about?
NCT03099538 is a clinical study titled "Ixekizumab in the Treatment of Bullous Pemphigoid". Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the...
What is the current status of trial NCT03099538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-08-15. Estimated completion is 2019-06-06.
What interventions are being tested in trial NCT03099538?
The interventions under investigation include: Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT03099538?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.